Table 1A

Continued

First author yearGeographic locationStudy sizeDNA sourceGenotyping methodaControl for ethnicitybControl samplingCase restrictionsaHWE pc
GroupaNCasesControls
Agorastos 2000GreeceNormal30Cervix archivalCervix freshASPRestrictionConvenienceNone0.14
SIL46
Cancer12
Malcolm 2000United StatesNormalNoneCervix archivalNo controlsASP; RFLPPrimarily CaucasianNo controlsNoneNo controls
SIL264
Cancer159
Tenti 2000ItalyNormal140Cervix archivalCervix freshASP; RFLPRestrictionConvenienceNone0.86
Cancer101
Makni 2000BrazilNormalh73Cervix freshCervix freshASP at three labsAdjusted in analysisRisk-based (hospital)None<0.10
Cancer38
Nishikawa 2000JapanNormalNoneCervix freshNo controlsASPRestrictionNo controlsNoneNo controls
SIL27
Cancer85
Pegoraro 2000South AfricaNormal251BloodBloodASPRestrictionRisk-basedNone0.80
Cancer121
Kucera 2000AustriaNormal133BloodBloodOtheriMatchingRisk-basedNone0.05
SIL50
Cancer105
Kim 2001KoreaNormal100BloodBloodASPRestrictionRisk-basedHPV16+0.27
SIL134
Cancer100
Zehbe 2001SwedenNormalf188Cervix archivalCervix archivalSSCPN.S.ConvenienceHPV16+0.21
SIL94
Cancer72
Zehbe 2001ItalyNormalf,j40Cervix archivalBloodSSCPRestrictionConvenience (babies)HPV16+0.59
SIL37
Cancer43
Gustafsson 2001SwedenNormalk36Cervix archivalCervix archivalDS done twiceRestrictionConvenienceNone0.20
SIL46
Cancer59
Rezza 2001ItalyNormal172Cervix archivalCervix archivalRFLPRestrictionRisk-based (cohort)None0.95
SIL71
Klug 2001PeruNormal127BloodBloodRFLPAdjusted in analysislRisk-based (hospital)None0.07
Cancer119
Andersson 2001SwedenNormal188Cervix archivalCervix freshSSCPNot clearConvenienceNone0.59
Cancer111
Humbey 2002FranceNormal50Cervix freshCervix freshDGGE; DSRestrictionRisk-basedNone0.03
SILd68
Saranath 2002IndiaNormal131BloodBloodASPRestrictionConvenienceNone0.00
Cancer134
Pegoraro 2002South AfricaNormal340BloodBloodASPRestrictionRisk-based (hospital)None0.85
Cancer281
Calhoun 2002United StatesNormal108Cervix freshBloodDSNoneConvenienceNone0.33
Cancer127
Suárez-Rincón 2002MexicoNormal52Cervix archivalCervix archivalRFLPNoneConvenienceNone0.03
Cancer38
Bhattacharya 2002IndiaNormal201Cervix freshCervix freshRFLPRestrictionRisk-based (neighbors)None0.14
Cancer55
Kawamata 2002JapanNormal112Cervix freshCervix freshASP; DSRestrictionConvenienceNone0.50
SIL44
Cancer44
Pillai 2002IndiaNormal110BloodBloodASPRestrictionRisk-basedNonem0.45
SIL128
Cancer183
Arbel-Alon 2002IsraelNormal162BloodBloodASPAdjustmentnRisk-based (population)None0.00
Cancer23
Nagpal 2002IndiaNormal29Cervix freshCervix freshASPRestrictionRisk-based (hospital)None0.03
SIL39
Cancer71
  • a SIL, Squamous intraepithelial lesions; ASP, allele-specific PCR; RFLP, restriction fragment length polymorphism; SSCP, single strand conformation polymorphism; DS, DNA sequencing; DGGE, denaturant gradient gel electrophoresis; HPV, human papillomavirus.

  • b N.S., not specified.

  • c P for χ-square test of statistically significant deviations from Hardy-Weinberg equilibrium (HWE).

  • d Cases not histologically confirmed.

  • e Same controls as in Josefsson 1998; sensitivity analyses excluding either or both studies did not change the results of the meta-analyses or regressions.

  • f Controls all HPV-negative.

  • g Archival samples used for cancer cases; Fresh cervical samples used for SIL cases.

  • h HPV-positive controls over-sampled.

  • i Allele-specific hybridization done after PCR step.

  • j Same controls as in Zehbe 1999; sensitivity analyses excluding either or both studies did not change the results of the meta-analyses or regressions.

  • k Controls histologically defined as non-neoplastic (normal cervicitis, hyperplasia, metaplasia, condyloma) - high-risk HPV-positive controls preferentially selected.

  • l In meta-analysis and regression, we used the crude OR; thus, Klug et al categorized as not having controlled for race.

  • m Of the HPV-positive cases, only the HPV16-positive included but HPV negative also included.

  • n We calculated adjusted OR from the raw data provided in the article.